Peptide-based blood coagulant - Haemostatix

Drug Profile

Peptide-based blood coagulant - Haemostatix

Alternative Names: Haemostasis therapeutic - Haemostatix; Haemostat topical - Haemostatix; PeproStat; PeproStat Liquid; Peptide-based antihaemorrhagic - Haemostatix

Latest Information Update: 05 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Haemostatix
  • Class
  • Mechanism of Action Fibrinogen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Surgical blood loss

Most Recent Events

  • 23 Oct 2017 Top-line safety and adverse events data from a phase II trial in Surgical blood loss (Prevention) released by Ergomed
  • 11 Oct 2017 Haemostatix completes the phase II CLOTFAST 2 trial in Surgical blood loss (Prevention) in United Kingdom, Poland, Bosnia and Herzegovina, Croatia, and Serbia (Topical) (NCT03131336)
  • 27 Sep 2017 PeproStat™ licensed to Boryung Pharmaceutical in South Korea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top